VERO Biotech
226 employees on LinkedIn · 4 known investors
VERO Biotech develops next-generation inhaled nitric oxide (iNO) delivery systems for patients with cardiopulmonary conditions in acute care hospital settings. The company focuses on designing and commercializing innovative medical devices to address unmet clinical needs.
Investors · 4
Brace PharmaAtlanta
Runway Growth CapitalMenlo Park · $10M – $150M
MVM Life Science PartnersreportedLondon · $20M – $100M
Also in the syndicate · 1
Petrichorlead
Competitors · 2
by search overlap
Vero Bioscience14 shared keywordsVero BioScience develops a blood-based proteomic test that measures organ-specific protein signatures to assess the biological age of individual organs and detect early signs of age-related disease. The company targets individuals seeking predictive health insights and preventive medicine interventions based on technology developed at Stanford.
Preqin13 shared keywordsPreqin provides a data and intelligence platform for investment teams, M&A professionals, and corporate development teams to source, evaluate, and value private company investments through integrated asset, fund, and performance data.
Companies competing with VERO Biotech for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does VERO Biotech do?
- VERO Biotech develops next-generation inhaled nitric oxide (iNO) delivery systems for patients with cardiopulmonary conditions in acute care hospital settings. The company focuses on designing and commercializing innovative medical devices to address unmet clinical needs.
- Who are VERO Biotech's investors?
- VERO Biotech's investors include Brace Pharma, Runway Growth Capital, MVM Life Science Partners.